annual EBITDA:
-$129.23M-$60.23M(-87.28%)Summary
- As of today (September 16, 2025), EYPT annual EBITDA is -$129.23 million, with the most recent change of -$60.23 million (-87.28%) on December 31, 2024.
- During the last 3 years, EYPT annual EBITDA has fallen by -$79.08 million (-157.69%).
- EYPT annual EBITDA is now -1140.72% below its all-time high of $12.42 million, reached on June 30, 2010.
Performance
EYPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$61.69M-$13.35M(-27.61%)Summary
- As of today (September 16, 2025), EYPT quarterly EBITDA is -$61.69 million, with the most recent change of -$13.35 million (-27.61%) on June 30, 2025.
- Over the past year, EYPT quarterly EBITDA has dropped by -$27.50 million (-80.46%).
- EYPT quarterly EBITDA is now -393.48% below its all-time high of $21.02 million, reached on September 30, 2014.
Performance
EYPT quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$187.14M-$27.50M(-17.23%)Summary
- As of today (September 16, 2025), EYPT TTM EBITDA is -$187.14 million, with the most recent change of -$27.50 million (-17.23%) on June 30, 2025.
- Over the past year, EYPT TTM EBITDA has dropped by -$89.41 million (-91.49%).
- EYPT TTM EBITDA is now -1607.14% below its all-time high of $12.42 million, reached on June 30, 2010.
Performance
EYPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
EYPT EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -87.3% | -80.5% | -91.5% |
3 y3 years | -157.7% | -233.2% | -174.6% |
5 y5 years | -169.2% | -488.5% | -334.9% |
EYPT EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -157.7% | at low | -331.9% | at low | -174.6% | at low |
5 y | 5-year | -264.1% | at low | -4663.6% | at low | -505.5% | at low |
alltime | all time | -1140.7% | at low | -393.5% | at low | -1607.1% | at low |
EYPT EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | -$61.69M(+27.6%) | -$187.14M(+17.2%) |
Mar 2025 | - | -$48.34M(+8.0%) | -$159.64M(+10.6%) |
Dec 2024 | -$129.23M(+87.3%) | -$44.77M(+38.4%) | -$144.31M(+24.6%) |
Sep 2024 | - | -$32.34M(-5.4%) | -$115.78M(+18.5%) |
Jun 2024 | - | -$34.18M(+3.5%) | -$97.73M(+13.4%) |
Mar 2024 | - | -$33.02M(+103.3%) | -$86.17M(+15.5%) |
Dec 2023 | -$69.00M(-28.6%) | -$16.24M(+13.7%) | -$74.60M(-8.0%) |
Sep 2023 | - | -$14.28M(-36.9%) | -$81.06M(-4.0%) |
Jun 2023 | - | -$22.63M(+5.5%) | -$84.47M(+5.1%) |
Mar 2023 | - | -$21.45M(-5.5%) | -$80.35M(+5.0%) |
Dec 2022 | -$96.62M(+92.7%) | -$22.70M(+28.3%) | -$76.49M(+7.5%) |
Sep 2022 | - | -$17.69M(-4.5%) | -$71.14M(+4.4%) |
Jun 2022 | - | -$18.51M(+5.3%) | -$68.15M(+13.7%) |
Mar 2022 | - | -$17.59M(+1.4%) | -$59.93M(+14.0%) |
Dec 2021 | -$50.15M(+41.3%) | -$17.35M(+18.1%) | -$52.59M(+11.2%) |
Sep 2021 | - | -$14.70M(+42.8%) | -$47.31M(+39.5%) |
Jun 2021 | - | -$10.29M(+0.4%) | -$33.91M(-0.6%) |
Mar 2021 | - | -$10.25M(-15.1%) | -$34.09M(-1.6%) |
Dec 2020 | -$35.49M(-26.1%) | -$12.07M(+831.9%) | -$34.64M(+12.1%) |
Sep 2020 | - | -$1.29M(-87.6%) | -$30.91M(-28.2%) |
Jun 2020 | - | -$10.48M(-2.9%) | -$43.03M(+2.3%) |
Mar 2020 | - | -$10.80M(+29.5%) | -$42.06M(-7.1%) |
Dec 2019 | -$48.01M(+15.0%) | -$8.34M(-37.9%) | -$45.26M(+22.6%) |
Sep 2019 | - | -$13.41M(+41.0%) | -$36.92M(+57.1%) |
Jun 2019 | - | -$9.52M(-32.0%) | -$23.51M(+68.0%) |
Mar 2019 | - | -$13.99M(+136.3%) | -$13.99M(-19.1%) |
Dec 2018 | -$41.75M(+136.3%) | - | - |
Jun 2017 | -$17.67M(-15.0%) | -$5.92M(+19.6%) | -$17.29M(-1.6%) |
Mar 2017 | - | -$4.95M(-3446.6%) | -$17.57M(+0.2%) |
Dec 2016 | - | $148.00K(-102.3%) | -$17.54M(-22.9%) |
Sep 2016 | - | -$6.56M(+5.7%) | -$22.74M(+8.4%) |
Jun 2016 | -$20.79M(-384.7%) | -$6.21M(+26.2%) | -$20.99M(+6.2%) |
Mar 2016 | - | -$4.92M(-2.7%) | -$19.76M(+0.4%) |
Dec 2015 | - | -$5.06M(+5.2%) | -$19.68M(+6.2%) |
Sep 2015 | - | -$4.81M(-3.4%) | -$18.52M(-353.7%) |
Jun 2015 | $7.30M(-157.7%) | -$4.98M(+2.8%) | $7.30M(-14.1%) |
Mar 2015 | - | -$4.84M(+24.1%) | $8.50M(-25.1%) |
Dec 2014 | - | -$3.90M(-118.6%) | $11.35M(-4.3%) |
Sep 2014 | - | $21.02M(-655.8%) | $11.86M(-193.7%) |
Jun 2014 | -$12.65M(+14.6%) | -$3.78M(+89.9%) | -$12.65M(+0.4%) |
Mar 2014 | - | -$1.99M(-41.2%) | -$12.60M(-4.3%) |
Dec 2013 | - | -$3.39M(-2.8%) | -$13.17M(+8.1%) |
Sep 2013 | - | -$3.49M(-6.6%) | -$12.18M(+10.4%) |
Jun 2013 | -$11.04M | -$3.73M(+45.6%) | -$11.04M(+18.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2013 | - | -$2.56M(+6.9%) | -$9.34M(+0.8%) |
Dec 2012 | - | -$2.40M(+2.4%) | -$9.27M(+5.1%) |
Sep 2012 | - | -$2.34M(+14.9%) | -$8.82M(+8.2%) |
Jun 2012 | -$22.78M(+315.8%) | -$2.04M(-18.1%) | -$8.15M(+46.4%) |
Mar 2012 | - | -$2.49M(+27.7%) | -$5.57M(+3.6%) |
Dec 2011 | - | -$1.95M(+16.5%) | -$5.37M(-5.9%) |
Sep 2011 | - | -$1.67M(-406.0%) | -$5.71M(-14.1%) |
Jun 2011 | -$5.48M(-144.1%) | $547.00K(-123.8%) | -$6.65M(-215.0%) |
Mar 2011 | - | -$2.29M(+0.4%) | $5.78M(-4.2%) |
Dec 2010 | - | -$2.29M(-12.5%) | $6.03M(-33.4%) |
Sep 2010 | - | -$2.61M(-120.1%) | $9.06M(-27.1%) |
Jun 2010 | $12.42M(<-9900.0%) | $12.97M(-736.0%) | $12.42M(+5757.1%) |
Mar 2010 | - | -$2.04M(-377.2%) | $212.00K(-90.6%) |
Dec 2009 | - | $736.00K(-1.5%) | $2.27M(+136.3%) |
Sep 2009 | - | $747.00K(-2.9%) | $959.00K(-180.1%) |
Jun 2009 | -$24.00K(-100.0%) | $769.00K(+5392.9%) | -$1.20M(-79.9%) |
Mar 2009 | - | $14.00K(-102.5%) | -$5.97M(-48.4%) |
Dec 2008 | - | -$571.00K(-59.5%) | -$11.57M(-35.5%) |
Sep 2008 | - | -$1.41M(-64.8%) | -$17.93M(-13.1%) |
Jun 2008 | -$71.36M(+166.0%) | -$4.01M(-28.2%) | -$20.62M(-61.8%) |
Mar 2008 | - | -$5.58M(-19.4%) | -$53.93M(+11.7%) |
Dec 2007 | - | -$6.93M(+68.9%) | -$48.29M(-3.2%) |
Sep 2007 | - | -$4.10M(-89.0%) | -$49.86M(+10.9%) |
Jun 2007 | -$26.82M(+41.4%) | -$37.32M(<-9900.0%) | -$44.97M(+23.6%) |
Mar 2007 | - | $65.00K(-100.8%) | -$36.38M(+0.8%) |
Dec 2006 | - | -$8.50M(-1175.4%) | -$36.09M(+34.1%) |
Sep 2006 | - | $790.40K(-102.8%) | -$26.92M(-1.5%) |
Jun 2006 | -$18.98M(+101.1%) | -$28.73M(-8264.7%) | -$27.33M(+100.5%) |
Mar 2006 | - | $351.90K(-47.5%) | -$13.63M(-1.4%) |
Dec 2005 | - | $670.70K(+78.8%) | -$13.82M(-3.6%) |
Sep 2005 | - | $375.10K(-102.5%) | -$14.33M(-1.5%) |
Jun 2005 | -$9.44M(+57.4%) | -$15.03M(-9470.5%) | -$14.56M(+143.3%) |
Mar 2005 | - | $160.40K(-0.9%) | -$5.98M(-1.4%) |
Dec 2004 | - | $161.80K(+7.4%) | -$6.07M(-1.5%) |
Sep 2004 | - | $150.70K(-102.3%) | -$6.16M(-1.4%) |
Jun 2004 | -$6.00M(+77.1%) | -$6.46M(-8954.7%) | -$6.25M(+81.7%) |
Mar 2004 | - | $72.90K(+1.5%) | -$3.44M(-1.6%) |
Dec 2003 | - | $71.80K(+10.6%) | -$3.49M(-1.6%) |
Sep 2003 | - | $64.90K(-101.8%) | -$3.55M(-1.4%) |
Jun 2003 | -$3.39M(+164.7%) | -$3.65M(<-9900.0%) | -$3.60M(-7728.4%) |
Mar 2003 | - | $16.70K(+7.7%) | $47.20K(+54.8%) |
Dec 2002 | - | $15.50K(+3.3%) | $30.50K(+103.3%) |
Sep 2002 | - | $15.00K | $15.00K |
Jun 2002 | -$1.28M(+194.2%) | - | - |
Jun 2001 | -$434.60K | - | - |
FAQ
- What is EyePoint Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for EyePoint Pharmaceuticals, Inc.?
- What is EyePoint Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals, Inc.?
- What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for EyePoint Pharmaceuticals, Inc.?
- What is EyePoint Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is EyePoint Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of EYPT is -$129.23M
What is the all time high annual EBITDA for EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. all-time high annual EBITDA is $12.42M
What is EyePoint Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, EYPT annual EBITDA has changed by -$60.23M (-87.28%)
What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of EYPT is -$61.69M
What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. all-time high quarterly EBITDA is $21.02M
What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, EYPT quarterly EBITDA has changed by -$27.50M (-80.46%)
What is EyePoint Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of EYPT is -$187.14M
What is the all time high TTM EBITDA for EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. all-time high TTM EBITDA is $12.42M
What is EyePoint Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, EYPT TTM EBITDA has changed by -$89.41M (-91.49%)